Medical/Pharmaceuticals

Live from ASCO 2024 | Oral Report Released Latest Data of Olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3%

SUZHOU, China and ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated clinical data of olvere...

2024-06-05 11:46 2302

Live from ASCO 2024 | Ascentage Pharma Releases Updated Data Showing Promising Efficacy and Safety of Lisaftoclax in Patients with WM

SUZHOU, China, and ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated results from a global,...

2024-06-05 11:31 2061

Dalton Pharma Services Invests in Robotic Aseptic Powder Fill-Finish Line from 3P innovation

TORONTO, June 5, 2024 /PRNewswire/ -- Pharmaceutical manufacturing company, Dalton Pharma Services (a Seikagaku Group company), has recently commissioned 3P innovation (Warwick, UK) to design and construct a fully automated state-of-the-art high-speed aseptic powder filling line to expedite the ...

2024-06-05 10:00 2174

RestoringVision Awarded $4 Million Grant to Restore Sight to 2.5 Million People with Presbyopia in India and Nigeria

SAN FRANCISCO, June 4, 2024 /PRNewswire/ -- RestoringVision has been awarded a $4 million grant from Founders Pledge to address presbyopia at scale in India andNigeria. This investment will enable RestoringVision to implement three large-scale initiatives with its partners to provide reading glas...

2024-06-04 22:32 2498

Zymo Research Unveils PureRec DSN: The Most Selective Duplex-Specific Nuclease

IRVINE, Calif., June 4, 2024 /PRNewswire/ -- Zymo Research, a leader in biotechnological advancement has launched a new nuclease calledPureRec Duplex-Specific Nuclease (DSN) that selectively digests double stranded DNA (dsDNA). This new PureRec DSN promises unparalleled specificity in targeting ...

2024-06-04 21:00 1670

CARsgen Presents Updated Results on Satri-cel in Nature Medicine and at 2024 ASCO

SHANGHAI, June 4, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the final follow-up results of the investigator-initiated trial C...

2024-06-04 20:50 2304

Masdar City to Showcase Its Life Sciences Hub at BIO24 in San Diego

Masdar City to showcase why they are the leading destination for the life sciences sector at BIO24 ABU DHABI, UAE, June 4, 2024 /PRNewswire/ -- Highlighting its growing status as a leading destination for the life sciences sector, Masdar City,Abu Dhabi's flagship sustainable city in theUnited Ar...

2024-06-04 19:57 4077

FDA Clearance For Gastrointestinal Parasite Detection Kit

MELBOURNE, Australia, June 4, 2024 /PRNewswire/ -- Genetic Signatures Limited [ASX:GSS]("GSS" or the "Company"), a global molecular diagnostics company announces that the US Food & Drug Administration ("FDA") has cleared the Company'sEasyScreen™ Gastrointestinal Parasite Detection Kit and GS1 aut...

2024-06-04 19:00 2027

Fosun International Garners Four Awards from Corporate Governance Asia

Chen Qiyu and Xu Xiaoliang, Executive Directors and Co-CEOs of Fosun International winAsia's Best CEO from Corporate Governance Asia Fosun International receives Sustainable Asia Award and Best Corporate Communications Award HONG KONG, June 4, 2024 /PRNewswire/ -- On 31 May 2024, the magazine  C...

2024-06-04 18:20 4024

Qingsong Health Corporation Elevates Healthcare and Inclusive Development with AI Advancements at WSIS+20 Forum

BEIJING, June 4, 2024 /PRNewswire/ -- At The World Summit on the Information Society (WSIS) Forum inGeneva, the Qingsong Health Corporation from China, known for its technology-driven healthcare solutions, showcased the latest AI advancements for improved and inclusive healthcare. The WSIS+20 For...

2024-06-04 16:04 1827

AmpleLogic Launches Advanced aPaaS for Life Sciences with 14 Ready-to-Use Applications

HYDERABAD, India, June 4, 2024 /PRNewswire/ -- AmpleLogic, a leading provider of GAMP solutions, announces the launch of its revolutionaryApplication Platform as a Service (aPaaS) designed specifically for the life sciences sector. This ...

2024-06-04 13:30 1742

GCBP Sponsors 2024 Spring Symposium for KASBP and Present Research Findings

YONGIN, South Korea, June 4, 2024 /PRNewswire/ -- GC Biopharma announced that it will attend 2024 Spring Symposium of the Korean American Society in Biotech and Pharmaceuticals (KASBP) onJune 7-8th at Waltham, Massachusetts as a sponsor to share keynote presentation, present Korean Scientist Awar...

2024-06-04 13:00 2214

Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety

SUZHOU, China and ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the latest results from a Phase...

2024-06-04 12:51 2209

Fapon Biopharma Announces a Safer Immunotherapy for Cancers

SAN DIEGO, June 3, 2024 /PRNewswire/ -- At Bio International Convention 2024, which is taking place here inSan Diego during June 3-6, Fapon Biopharma, an innovator in developing therapeutic antibodies and fusion proteins, has announced an immunocytokine with modified IL-10M fused to anti-PD-1 ant...

2024-06-04 09:42 1508

RemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for Self-Developed, Potential First-in-Class Antibody-Drug Conjugate RC88

YANTAI, China, June 4, 2024 /PRNewswire/ -- RemeGen Co., Ltd.  ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, presented the results of the first-in-human, single-arm, open-label, multi-center Phase I/II study evaluating RC8...

2024-06-04 09:38 2277

Waters Sets New Standards for High Resolution Performance and Speed with Xevo MRT Mass Spectrometer

News Summary: * Waters Xevo™ MRT Mass Spectrometer employs next-generation multi-reflecting time-of-flight technology to deliver class-leading combination of high resolution and speed without compromising analytical performance.i * Delivers up to 6x resolution at maximum speed and up to 2x ma...

2024-06-04 08:00 3368

Optimi Health Awarded Drug Establishment Licence From Health Canada

VANCOUVER, BC, June 3, 2024 /PRNewswire/ -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a leading Health Canada-licensed psychedelics pharmaceutical manufacturer specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to ...

2024-06-03 23:49 1471

BioCina Acquires the Exclusive CDMO Rights for Leading-Edge Minicircle DNA Technology Platform from CelluTx

ADELAIDE, South Australia, June 3, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced the exclusive rights to utilize CelluTx's Recombination Based Plasmid System (RBPS) technology with BioCina's CDMO clients....

2024-06-03 23:37 2971

Datasea Agreement already provided $2.8 million Information Service for its Highly Specialized 5G-AI Communications Platform

Agreement to Have Powerful Revenue Impact and is Expected to Lead to More Lucrative Contracts BEIJING, June 3, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada company engaged in innovative business segments in high-tech intelligent acoustics and 5G-Artifici...

2024-06-03 22:00 3803

Minghui Pharmaceutical Presents Phase 1/2 Clinical Data of MHB088C (B7-H3 ADC) as Monotherapy for the Treatment of Patients with Recurrent or Metastatic Solid Tumors at the 2024 ASCO Annual Meeting

SHANGHAI, June 3, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage clinical biopharmaceutical company, announced today that the preliminary Phase 1/2 clinical data of MHB088C (B7-H3 ADC) was presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in an ora...

2024-06-03 21:30 6629
1 ... 216217218219220221222 ... 645

Week's Top Stories